COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis

The rapidly evolving coronavirus disease 2019 (COVID-19), was declared a pandemic by the World Health Organization on March 11, 2020. It was first detected in the Wuhan city of China and has spread globally resulting in a substantial health and economic crisis in many countries. Observational studie...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in medicine Ročník 7; s. 459
Hlavní autoři: Nasiri, Mohammad Javad, Haddadi, Sara, Tahvildari, Azin, Farsi, Yeganeh, Arbabi, Mahta, Hasanzadeh, Saba, Jamshidi, Parnian, Murthi, Mukunthan, Mirsaeidi, Mehdi
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media SA 21.07.2020
Frontiers Media S.A
Témata:
ISSN:2296-858X, 2296-858X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The rapidly evolving coronavirus disease 2019 (COVID-19), was declared a pandemic by the World Health Organization on March 11, 2020. It was first detected in the Wuhan city of China and has spread globally resulting in a substantial health and economic crisis in many countries. Observational studies have partially identified different aspects of this disease. There have been no published systematic reviews that combine clinical, laboratory, epidemiologic, and mortality findings. Also, the effect of gender on the outcomes of COVID-19 has not been well-defined. We reviewed the scientific literature published from January 1, 2019 to May 29, 2020. Statistical analyses were performed with STATA (version 14, IC; Stata Corporation, College Station, TX, USA). The pooled frequency with 95% confidence intervals (CI) was assessed using random effect model. < 0.05 was considered a statistically significant publication bias. Out of 1,223 studies, 34 satisfied the inclusion criteria. A total of 5,057 patients with a mean age of 49 years were evaluated. Fever (83.0%, CI 77.5-87.6) and cough (65.2%, CI 58.6-71.2) were the most common symptoms. The most prevalent comorbidities were hypertension (18.5%, CI 12.7-24.4) and Cardiovascular disease (14.9%, CI 6.0-23.8). Among the laboratory abnormalities, elevated C-Reactive Protein (CRP) (72.0%, CI 54.3-84.6) and lymphopenia (50.1%, CI 38.0-62.4) were the most common. Bilateral ground-glass opacities (66.0%, CI 51.1-78.0) was the most common CT scan presentation. The pooled mortality rate was 6.6%, with males having significantly higher mortality compared to females (OR 3.4; 95% CI 1.2-9.1, = 0.01). COVID-19 has caused a significant number of hospitalization and mortality worldwide. Mortality associated with COVID-19 was higher in our study compared to the previous reports from China. The mortality was significantly higher among the hospitalized male group. Further studies are required to evaluate the effect of different variables resulting in sex disparity in COVID-19 mortality.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Reviewed by: Ricvan Dana Nindrea, Andalas University, Indonesia; Hui Wang, Shanghai Jiao Tong University, China
This article was submitted to Infectious Diseases, Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine
Edited by: Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France
These authors have contributed equally to this work
These authors share first authorship
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2020.00459